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Secondary pneumonia due to Staphylococcus aureus (S. aureus) causes significant morbidity and mortality. The aim
of the research was designed a novel DNA vaccine encoding the Mycobacterium tuberculosis secreted antigen
Ag85A fused with the influenza A virus (IAV) HA2 protein to provide protection against both influenza and
secondary infection with S. aureus. The DNA vaccine vector efficiently expressed the encoded antigen in
mammalian cells, as determined by RT-PCR, Western blotting and immunofluorescence analysis. Mice were
immunized with the vaccine by intramuscular injection before challenge with IAV and S. aureus. The pulmonary and
the splenocyte culture IFN-γ levels were significant higher in immunized mice than their respective controls.
Although the antibody titer in the HI test was low, the sera of mice immunized with the novel vaccine vector were
effective in neutralisation assay in vitro. The vaccine could reduce the loss of body weight in mice during IAV
challenge. Both Western blotting and RT-PCR showed that the vaccine markedly enhanced toll like receptor 2
(TLR2) expression in splenocytes after the secondary infection with S. aureus. The survival rate of mice with high
TLR2 expression (pEGFP/Ag85A-HA2 or iPR) was significantly increased compared with mice immunized with
pEGFP/HA2 after challenge with S. aureus. However, the pulmonary IL-10 concentration and S. aureus titer were
significantly decreased in immunized mice, and expression of TLR2 was increased after challenge with S. aureus.
These results demonstrated that Ag85A could strengthen the immune response to IAV and S. aureus, and TLR2 was
involved in the host response to S. aureus.
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vaccineIntroduction
Secondary pneumonia due to Staphylococcus aureus (S.
aureus) is a significant cause of mortality associated with
influenza A virus (IAV) infection [1,2]. Antibody
responses against the viral surface protein hemagglutinin
(HA) are major determinants for protection against IAV
[3]. However, variations in HA occur rapidly due to anti-
genic shift and drift, allowing the virus to evade immun-
ity conferred by seasonal vaccines [4]. Therefore,* Correspondence: lmy3985@sina.com
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reproduction in any medium, provided the ordevelopment of an IAV vaccine to enhance immune
responses to conserved domains of IAV and S. aureus
would be highly advantageous. HA is synthesized as a
precursor HA0, which is cleaved into the HA1 and HA2
subunits. While the membrane distal domain (HA1) can
be highly variable, the stalk region of HA, which con-
tains the core fusion machinery constituted primarily by
the HA2 subunit, is relatively conserved. Antibodies tar-
geting the HA2 subunit can provide broad protection
against both seasonal and pandemic influenza A infec-
tions [5]. However, weak antigenicity [6] is one of the
reasons that outbreaks of IAV and secondary pneumonia
cannot be prevented by vaccination with the fusion pep-
tide alone. It would therefore be beneficial for a vaccine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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aureus infections.
The Bacille Calmette-Guérin (BCG) vaccine against
Mycobacterium tuberculosis has been shown to have a
marked immunomodulatory effect in combination with
influenza vaccines and can enhance antigen-specific
antibody production. Sera from mice vaccinated with
BCG exhibit antibacterial activity [7]. Ag85A, as a major
secreted antigen of M. tuberculosis and an immunodo-
minant antigen of BCG, can increase T helper type 1
(Th1) cytokine responses [8]. The Th1 cytokine, inter-
feron (IFN)-γ, can upregulate expression of toll-like re-
ceptor 2 (TLR2), which recognizes Staphylococcal
peptidoglycans and induces activation of immune
responses [9]. As it is possible that Ag85A can upregu-
late TLR2 expression and immune activation has been
shown to offer protection against S. aureus, we therefore
hypothesized that immune reactions to Ag85A may be
able to eliminate this bacteria [10,11]. Although the
upregulation of TLR2 may be helpful against bacterial
infection, it has been suggested that TLR2 does not con-
tribute to host responses during post-influenza pneumo-
nia [12], Therefore, it is not yet clear whether
upregulation of TLR2 would be beneficial in such a
scenario.
We constructed a novel influenza vaccine construct
expressing a conserved region of the HA protein linked
with Ag85A to evaluate whether M. tuberculosis secreted
antigen Ag85A may serve as a good immune adjuvant
for HA2. The efficacy of this vaccine in preventing mor-
bidity after challenge with IAV and mortality in mice
was evaluated after challenge with IAV and S. aureus,
and cytokine profiles were determined in lung homoge-
nates and cultured splenocytes. We also explored the
role of TLR2 upregulation in post-influenza pneumonia.
Results
Expression of Ag85A and/or HA2 from plasmid DNA
vectors in eukaryotic cells
pEGFP/Ag85A-HA2, pEGFP-C2, pEGFP/Ag85A and
pEGFP/HA2 were successfully transfected in HEK293
cells. Strong green fluorescent signals were clearly seen
in the cells transfected with all four plasmids
(Figure 1A). The results of RT-PCR (Figure 1B) and
western blotting (Figure 1C) also confirmed that pEGFP/
Ag85A-HA2, pEGFP/Ag85A and pEGFP/HA2 success-
fully expressed the expected transcripts in transfected
HEK293 cells. Therefore, the Ag85A, HA2 and the
Ag85A-HA2 fusion genes could be transiently expressed
in HEK 293 cells.
Comparison of antibody titers and influenza virus loads
The mice were inoculated with pEGFP/Ag85A-HA2,
pEGFP/HA2, pEGFP/Ag85A, PBS, pEGFP/C2 or iPR.Development of antibodies against HA was evaluated by
hemagglutination inhibition (HI) assays. The HI titers
were represented as group means of log 2 dilution. As
shown in Table 1, the highest HI titer against PR8 virus
was detected in mice immunized with iPR, which
increased by approximately 3-fold after boosting. How-
ever, HI activity against PR8 virus was not detected in
mice immunized with pEGFP/HA2 or pEGFP/Ag85A-
HA2. The HI antibody titers were low (<10) in these
groups both in the primary response and in the booster
response, as might be expected based on the absence of
the HA1 antigen in the vaccine which could induce anti-
bodies to the receptor binding site or other epitopes
involved in HI.
Development of neutralizing antibodies (NAbs) against
HA was evaluated by the neutralisation assay. The titer
of each serum sample was expressed as the dilution (log
2 transformed) that decreased the CPE due to the inocu-
lating virus by 50% in MDCK cells. As shown in Figure 2,
The NAb titer of the pEGFP/HA2 vaccinated group was
higher than those of the pEGFP-C2, PBS and pEGFP/
Ag85A vaccinated groups (P < 0.05). High NAb titers
were detected in mice immunized with iPR, pEGFP/
Ag85A-HA2 and pEGFP/HA2. The NAb titer from the
pEGFP/Ag85A-HA2 vaccinated group was higher than
those of the pEGFP-C2, pEGFP/HA2 and pEGFP/Ag85A
vaccinated groups (P < 0.05).
However, influenza virus loads decreased in mice
immunized with iPR, pEGFP/HA2 or pEGFP/Ag85A-
HA2 (Table 1) (P < 0.05). The influenza virus titers of
samples from the pEGFP/Ag85A-HA2 vaccinated group
was lower than that of the pEGFP-C2, pEGFP/HA2 and
pEGFP/Ag85A vaccinated groups (P < 0.05).
Cytokine measurements
In vitro IFN-γ production was evaluated 8 days after the
virus challenge. IFN-γ was induced by HA or conA
in vitro. IFN-γ production in the PBS group was mark-
edly lower than that of other groups when induced by
HA (P < 0.05). However, HA induced higher IFN-γ titers
in the pEGFP/Ag85A-HA2 group (Figure 3) (P < 0.05).
Splenocytes from mice vaccinated with pEGFP/Ag85A-
HA2 produced 1.5-fold higher IFN-γ in response to
HA than those from mice vaccinated with pEGFP/HA2
(P < 0.05). HA induced markedly lower IFN-γ levels
than did conA (data not shown).
We measured IL-10 and IFN-γ in lung homogenates
on day 8 after infection with A/PR/8/34 and at day 2
after infection with S. aureus. Some differences were
found between the pEGFP/Ag85A-HA2 group and other
groups. In particular, the pulmonary IFN-γ levels were
significantly higher in the pEGFP/Ag85A-HA2 vacci-
nated group on day 8 after infection with A/PR/8/34
(Figure 4A). The pulmonary IFN-γ levels of mice
Figure 1 Expression of HA2 or Ag85A in HEK293 cells. (A) Expression of HA2 or Ag85A in HEK293 cells. HEK293 cells were transfected
with plasmids encoding individual HA2 or Ag85A proteins or the Ag85A-HA2 fusion protein, and expression was evaluated by GFP fluorescence.
Shown are cells transfected with pEGFP/HA2 (a, b), pEGFP/Ag85A (c, d), pEGFP/C2 (e, f), pEGFP/Ag85A-HA2 (g, h) or untransfected cells (i, j).
Fluorescent images (a, c, e, g, i) and phase contrast images (b, d, f, h, j) are shown. (B) Expression was evaluated by RT-PCR. (7) cells transfected
with pEGFP/ HA2; (3,6,9) Trans2K Plus DNA Marker; (2,5,8) cells transfected with pEGFP-C2; (4) cells transfected with pEGFP/Ag85A; (1) cells
transfected with pEGFP/ Ag85A-HA2. Fragments of approximately 1500 bp (1), 750 bp (4, 7) and 500 bp (1, 2, 4, 5, 7 and 8) were separated by 2%
agarose gel electrophoresis following RT-PCR. GADPH: Fragments of approximately 500 bp; pEGFP/Ag85A: Fragments of approximately 750 bp;
pEGFP/ HA2: Fragments of approximately 750 bp; pEGFP/ Ag85A-HA2: Fragments of approximately 1500 bp. (C) Expression was evaluated by
Western blotting. (a) cells transfected with pEGFP/ Ag85A-HA2; (b) cells transfected with pEGFP-C2; (c) cells transfected with PBS; (d) cells
transfected with pEGFP/ HA2; (e) cells transfected with pEGFP/Ag85A.
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higher than those vaccinated with pEGFP/HA2 on day 8
after infection with A/PR/8/34 (P < 0.05). The pulmon-
ary IFN-γ levels of mice vaccinated with pEGFP/HA2
were significantly higher than those vaccinated with
pEGFP-C2 or PBS (P < 0.05). The pulmonary levels of
the anti-inflammatory cytokine IL-10 were significantly
higher in the PBS group and the pEGFP-C2 vaccinated
group than those in the other groups at day 2 after in-
fection with S. aureus (P < 0.05). However, the levels ofIL-10 were lower in the pEGFP/Ag85A-HA2 vaccinated
group on day 2 after infection with S. aureus (P < 0.05)
(Figure 4B).
Expression of TLR2
In vivo expression of TLR2 was evaluated by Western
blotting and RT-PCR 2 days after S. aureus challenge.
Splenocyte TLR2 expression in mice vaccinated with
pEGFP/Ag85A-HA2 or iPR was higher than those in
their respective controls, and there was no difference
Table 1 Comparison of influenza virus load and antibody titers
Group Lung virus titer (log10 TCID50) Antibody titer (HI assay)
Primary response Secondary response
inactivated PR 2.17 ± 0.58 9 ± 5.03 24 ± 9.24
pEGFP/Ag85A-HA2 3.67 ± 0.77 4.5 ± 2.52 8 ± 5.66
pEGFP/Ag85A 6.17 ± 0.57 1.5 ± 1.91 2.5 ± 1.71
pEGFP/HA2 4.67 ± 0.98 3 ± 1.15 4.5 ± 2.52
pEGFP/C2 6.83 ± 0.94 0.5 ± 1.00 0.5 ± 1.00
PBS 6.92 ± 0.79 0.5 ± 1.00 0.5 ± 1.00
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(Figure 5A,B).
Comparison of body weight loss, survival rate and
bacterial outgrowth during post-influenza pneumonia
As IAV infection can induce body weight loss, it can be
used to follow the course of infection in mice. At 14 days
after infection with influenza, mice of all groups were
intranasally inoculated with S. aureus. Marked body
weight loss was detected 48 h after infection. Body
weight decreased obviously in the PBS, pEGFP/HA2,
pEGFP/Ag85A and pEGFP-C2 groups. The body weight
of the pEGFP/Ag85A-HA2 and iPR groups did not
change (P < 0.05 vs. mice of PBS group, pEGFP/HA2
group, pEGFP/Ag85A group and pEGFP/C2 group)
(Figure 6A). And survival rate decreased obviously in
the PBS and pEGFP-C2 groups after infection with IAV
(Figure 6B).
The survival rate was monitored from day 3 after in-
fection with S. aureus. In the PBS group, only two mice
survived for 3 days and no mice survived 4 days after S.
aureus challenge (data not shown). The survival rate was
high in the pEGFP/Ag85A-HA2 and iPR groups, while it
was low in other groups. There were significant differ-
ences in the survival rates between the pEGFP/Ag85A-
HA2 group or iPR group and other groups (P < 0.05)
(Figure 7). The survival rate of mice vaccinated with
pEGFP/Ag85A-HA2 was significantly higher than that of
mice vaccinated with pEGFP/HA2 (P < 0.05). The sur-
vival rate of mice vaccinated with pEGFP/HA2 was sig-
nificantly higher than that of mice vaccinated with
pEGFP-C2 or PBS. Additionally, we did not find a sig-
nificant difference between the pEGFP/Ag85A-HA2
group and iPR group (P > 0.05) (Figure 7).
S. aureus titration was performed to further assess the
host defense against secondary Staphylococcal infection.
The S. aureus titer in mice vaccinated with pEGFP/
Ag85A-HA2 or iPR was lower than that in mice vacci-
nated with pEGFP/HA2, pEGFP/Ag85A or PBS (P < 0.05)
(Figure 8).Discussion
Variability of IAV is one of the difficulties in developing
prophylactic vaccines. Once infected with IAV, second-
ary respiratory tract infections caused by S. aureus is
also problematic [13-15]. Post-influenza staphylococcal
pneumonia is associated with a strong inflammatory re-
sponse in the lungs [16,17]. Therefore, it is important
for novel influenza virus vaccines to provide protection
from S. aureus as well.
In this study, we developed a DNA vaccine encoding
the Ag85A-HA2 fusion protein with the aim of inducing
protection against both IAV and S. aureus. After con-
firming that they could express successfully in mamma-
lian cells, the novel vaccine and respective controls were
used to immunize mice by the intramuscular route be-
fore challenge with IAV and S. aureus. It was interesting
that while the antibody titer in the HI test was low, the
sera of mice immunized with the novel vaccine vector
were effective in neutralisation assay in vitro. The vac-
cine could reduce the loss of body weight in mice during
IAV challenge. This observation is supported by a previ-
ous study describing neutralizing antibodies to HA2
which could not completely prevent hemagglutination of
erythrocytes [5]. These results demonstrated that the im-
mune responses to HA2 was successfully induced by the
pEGFP/Ag85A-HA2 vaccine. Further tests are warranted
to determine whether these responses to HA2 may con-
fer protection against diverse IAV.
IFN-γ is a representative Th1 cytokine associated with
inhibition of IAV proliferation. Analysis of cytokine pro-
duction showed that the pulmonary IFN-γ levels in the
pEGFP/HA2 group were significantly higher than those
of the pEGFP-C2 and PBS groups after IAV challenge.
HA induced higher IFN-γ titers in the pEGFP/Ag85A-
HA2 group and pEGFP/ HA2 group (P < 0.05). Spleno-
cytes from mice vaccinated with pEGFP/Ag85A-HA2
produced 1.5-fold higher IFN-γ in response to HA than
those from mice vaccinated with pEGFP/HA2 (P < 0.05).
The weight loss of mice vaccinated with pEGFP/HA2






















Figure 2 Comparison of serum antibody titers (log 2 dilution) giving 50% CPE inhibition assay in MDCK cells. (*P < 0.05). The high NAb
titers were detected in mice immunized with iPR, pEGFP/Ag85A-HA2 and pEGFP/HA2. The NAb titer from the pEGFP/Ag85A-HA2 vaccinated
group was higher than those of the pEGFP-C2, pEGFP/HA2 and pEGFP/Ag85A vaccinated groups (P < 0.05). The NAb titer of the pEGFP/HA2
vaccinated group was higher than those of the pEGFP-C2, PBS and pEGFP/Ag85A vaccinated groups (P < 0.05).
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vaccinated with pEGFP/HA2 was higher than that of
mice vaccinated with pEGFP-C2 or PBS. However, the
weight loss after IAV challenge and the survival rate after
S. aureus challenge in the pEGFP/HA2 group were lower
than those in the iPR group. These result confirmed that
HA2 could provide limited protection against IAV and S.
aureus challenge.
The cytokine analysis also showed that the pulmonary
IFN-γ levels in the pEGFP/Ag85A-HA2 vaccinated
group were significantly higher than that in the



















Figure 3 IFN-γproduction in splenocyte culture 72 h after induced by
Ag85A-HA2 group (P < 0.05). Splenocytes from mice vaccinated with pEGFP
those from mice vaccinated with pEGFP/HA2 (P < 0.05).vaccinated with pEGFP/Ag85A-HA2 produced 1.5-fold
higher IFN-γ in response to HA than those from mice
vaccinated with pEGFP/HA2 (P < 0.05). These results
showed that pEGFP/Ag85A-HA2 could induce high
Th1 response. The weight loss of mice vaccinated with
pEGFP/Ag85A-HA2 was lower than that of mice vacci-
nated with pEGFP/HA2. The IAV titer in the pEGFP/
Ag85A-HA2 group was lower than those of the
pEGFP-C2, pEGFP/HA2 and pEGFP/Ag85A group.
These results demonstrated that Ag85A could enhance
the protective effects against IAV. The survival rate
after S. aureus challenge in the pEGFP/Ag85A-HA2pEGFP-C2 pEGFP/Ag85A iPR
HA in vitro. *P < 0.05. HA induced higher IFN-γ titers in the pEGFP/
/Ag85A-HA2 produced 1.5-fold higher IFN-γ in response to HA than






































Figure 4 Cytokine levels in mouse lung homogenates. IFN-γ (*P < 0.05) (A) and IL-10 (*P < 0.05) (B) of lung homogenates day 8 after infection
with A/PR/8/34 and on day 2 after infection with S. aureus. The pulmonary IFN-γ levels of mice vaccinated with pEGFP/Ag85A-HA2 were
significantly higher than those vaccinated with pEGFP/HA2 on day 8 after infection with A/PR/8/34 (P < 0.05). The pulmonary IFN-γ levels of mice
vaccinated with pEGFP/HA2 were significantly higher than those vaccinated with pEGFP-C2 or PBS (P < 0.05). The pulmonary levels of the anti-
inflammatory cytokine IL-10 were significantly higher in the PBS group and the pEGFP-C2 vaccinated group than those in the other groups at
day 2 after infection with S. aureus (P < 0.05).
Figure 5 Expression of TLR2 in splenocytes of different
vaccinated groups on day 2 after infection with S. aureus.
(A) Western blot detection of TLR2 in splenocytes. Lane A: PBS
group; lane B pEGFP-C2 group; lane C pEGFP /HA2 group; lane D
pEGFP/Ag85A group; lane E pEGFP/Ag85A-HA2 group; lane F iPR
group. (B) RT-PCR detection of TLR2 in splenocytes. Lanes 1, 8:
pEGFP/Ag85A-HA2 group; lanes 2, 9: pEGFP-C2 group; lanes 3, 10:
pEGFP /HA2 group; lanes 4, 11: pEGFP/Ag85A group; lanes 5, 12: PBS
group; lanes 7, 13: iPR group. Lanes 1–5, 7: TLR2 (410 bp); lanes 8–
13: GADPH (531 bp); lanes 6, 14: marker.
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The S. aureus titers of the pEGFP/Ag85A-HA2 group
and iPR group were lower than that of the pEGFP/
HA2 group. The higher survival rate and the lower S.
aureus titer after challenge in the pEGFP/Ag85A-HA2
group was probably due to Ag85A-mediated immune
activation, which enhanced the protective effects of
HA2 against IAV challenge. The increased protection
against IAV challenge decreased the influenza virus
titer. As IAV can suppress the functions of immune
cells [18,19], it was possible that the elimination of
IAV could enhance those functions. In other words,
the decreased influenza virus titer may have enhanced
immune protection against S. aureus challenge.
TLR2 is considered important for sensing gram-
positive bacteria [20,21], and its upregulation has been
positively associated with increased concentrations of
Gram-positive bacteria [22]. TLR2 enhances neutrophil
activity of killing of S. aureus and promotes clearance of
S. aureus [10]. However, since TLR2 may not contribute
to host responses during post-influenza pneumonia [12],
it was previously not clear whether increasing TLR2
AB
Figure 6 A Body weight of mice. Weight was calculated relative to day 0. Data are mean ± SEM of four mice per group. B Survival rate of mice
after infection with IAV. Survival rate was calculated from infection with IAV to infection with S. aureus.
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Our results here showed that TLR2 expression in mice
vaccinated with pEGFP/Ag85A-HA2 or iPR was also
higher than that of mice vaccinated with pEGFP/HA2.
The survival rate of mice with high TLR2 expression was
significantly increased after challenge with S. aureus.
IL-10 is an important mediator of the enhanced sus-
ceptibility to staphylococcal pneumonia [23]. A high
level of IL-10 can result in increased bacterial outgrowth
and markedly increased lethality during secondary bac-
terial pneumonia. In our study the IL-10 levels in lung
homogenates were significantly lower in the pEGFP/Figure 7 Survival rate of mice from day 3 after infection with S. aureu
was significantly higher than their respective controls (P < 0.05).Ag85A-HA2 vaccinated group and the iPR vaccinated
group than those of other groups at day 2 after infection
with S. aureus (P < 0.05). These results demonstrated
that TLR2 was involved in the host response to S. aureus
and enhanced elimination of the bacteria, thereby redu-
cing the incidence of post-influenza pneumonia.
Interactions between TLR2 and their ligands typically
results in cellular activation and the production of in-
flammatory cytokines. IL-10 could inhibit production of
inflammatory cytokines by inhibition of MyD88 pathway.
It is possible that IL-10 inhibit immune reaction by
affecting the expression of TLR2. Infection of IAV coulds. The survival rate of mice vaccinated with pEGFP/Ag85A-HA2 or iPR
Figure 8 Bacterial outgrowth during postinfluenza pneumonia.
(*P < 0.05). S. aureus titration was performed on day 2 after
infection with S. aureus. The S. aureus titer in mice vaccinated with
pEGFP/Ag85A-HA2 was lower than that in mice vaccinated
with pEGFP/HA2.
Dai et al. Virology Journal 2013, 10:40 Page 8 of 12
http://www.virologyj.com/content/10/1/40increase the level of IL-10. Our results here showed that
TLR2 expression in mice vaccinated with pEGFP/
Ag85A-HA2 or iPR was also higher than pEGFP-C2 and
IL-10 level in mice vaccinated with pEGFP/Ag85A-HA2
or iPR was lower than that of mice vaccinated with
pEGFP-C2. These results demonstrated that IL-10 could
affect the expression of TLR2.
BCG vaccine has been used widely. Ag85A is an
immunodominant antigen of BCG. Therefore, the im-
mune reactions against Ag85A could be easily induced.
Our results showed that Ag85A could enhance immune
responses to HA2. Ag85A should be investigated as a
new adjuvant for influenza vaccines.
Conclusions
The pEGFP/Ag85A-HA2 vaccine induced Th1 type
responses in lungs and splenocytes of inoculated mice.
Increase survival after IAV infection and reduced bacter-
ial load after S. aureus challenge was associated with
vaccine-induced TLR2 expression. Altogether, our find-
ings indicate that Ag85A could enhance immune
responses to HA2 and should be investigated as a new
adjuvant for influenza vaccines.
Material and methods
Construction of eukaryotic expression plasmid vaccine
and preparation of the heat-inactivated influenza A/PR/8/
34 vaccine
pEGFP/Ag85A was constructed by first cloning the
Ag85A sequence (1–250 amino acids of N-terminus)
[24,25] from BCG, and pEGFP/HA2 was constructed by
cloning the HA2 sequence (360–530 amino acids of HA
N-terminal) from the IAV strain A/PR/8/34, H1N1 as
described previously [26]. These sequences contain theimmunodominant epitopes of Ag85A and HA2. The
hydrophilicity of the proximal 250 amino acids of
Ag85A is similar to that of the HA N-terminal amino
acids 290–321 [27]. Ag85A and HA2 were fused (desig-
nated as Ag85A-HA2) with a 5 glycine linker as
described previously [6,28]. The pEGFP/Ag85A-HA2
was constructed by inserting Ag85A-HA2 into pEGFP-
C2 (Clontech, USA). All inserted fragments were con-
firmed by restriction endonuclease digestion. Sequencing
was performed using an ABI Prism 377XL DNA sequen-
cer (Invitrogen, China). Large scale extraction and puri-
fication of pEGFP/Ag85A-HA2, pEGFP/Ag85A and
pEGFP/HA2 were performed using the EndoFree Plas-
mid Maxi kit (Qiagen, Germany).
Preparation of inactivated influenza A/PR/8/34 (iPR)
virus was carried out by heating at 60°C for 1 h as
described previously [28]. The vaccine was stored in −20°C
before use.
Cell transfections
HEK293 cells (CRL-1573™) were obtained from the
American Type Culture Collection (ATCC) Purified
eukaryotic expression plasmids pEGFP/Ag85A-HA2,
pEGFP/Ag85A, pEGFP-C2 and pEGFP/HA2 were trans-
fected into HEK293 cells by using Lipofectamine™ 2000
transfection reagent (Invitrogen, China) according to the
manufacturer’s instructions. Each plasmid was trans-
fected in triplicate wells, and PBS was applied as a mock
transfection control. Plasmid expression in all cell
groups was assessed by fluorescence microscopy 48 h
after transfection.
Total RNA of all groups was isolated as recommended
by the manufacturer (Transgene, China). Contaminating
genomic DNA was then eliminated from the RNA pre-
parations by using RNase-free DNase I (Biotake, China).
RT reactions were performed with EasyScript First-
Strand cDNA Synthesis SuperMix (Transgene, China).
cDNAs were amplified by PCR using 2× TransTaq High
Fidelity (HiFi) PCR SuperMix (Transgene, China) in a
50 μl reaction mixture in accordance with the manufac-
turer’s recommendations. The following PCR primer









trol PCRs using GAPDH primers were performed on
cDNA from the pEGFP/Ag85A-HA2, pEGFP/Ag85A,
pEGFP-C2 and pEGFP/HA2 groups. Test PCRs of the
pEGFP-C2 group were performed with pEGFP/HA2
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primers. Test PCRs of the pEGFP/Ag85A-HA2, pEGFP/
Ag85A and pEGFP/HA2 groups were performed with
their respective primers. All PCRs were performed simul-
taneously in the same conditions: 5 min at 95°C, followed
by the appropriate number of cycles consisting of 30 sec
at 95°C, 30 sec at 50°C and 2 min at 72°C. After amplifica-
tion, 10 μl of each PCR product was electrophoresed on a
2% agarose gel and visualized by ethidium bromide stain-
ing. PCR amplification and sequencing were performed
using an ABI Prism 377XL DNA sequencer (Invitrogen,
China).
Cells of all group were lysed in RIPA sample buffer
(Boster Biological Technology) per the manufacturer’s
instructions, and supernatants were collected to analyze
expression of plasmids. The samples were separated by
SDS-PAGE (10%), and the proteins were transferred to
PVDF membranes, which were blocked for 2 h in 5%
nonfat dry milk in TBST (TBS containing 0.05% Tween-
20) and hybridized at 4°C overnight in TBST with the
primary antibodies (anti-HA, Catalog Number: 11055-
RP02, Sino Biological Inc, china; anti-Ag85A, Catalog
Number: ab14073, Abcam, UK). After washing the
membranes three times in TBST, for 15 min each time,
they were incubated with 1:10,000 dilutions of HRP-
conjugated secondary antibodies (Boster Biotechno-
logical). The membranes were washed three times in
TBST, for 15 min each time, and the blots were visua-
lized with an electrochemiluminescence (ECL) system
(Boster Biological Technology).Influenza infection and post-influenza pneumonia
induced by S. aureus challenge
A total of 84 female BALB/c mice, aged four to six
weeks old, were purchased from the animal care center
of Sichuan University and divided into 6 groups, with 14
mice in each group. They were bred under pathogen-
free conditions. Each group of mice was injected separ-
ately with one of the following: pEGFP/Ag85A-HA2,
pEGFP/Ag85A, pEGFP/HA2, pEGFP/c2, PBS, iPR. The
mice were immunized by intramuscular injection of the
quadriceps of both legs (50 μg in 50 μL PBS for each
leg) twice with a 3 week interval between injections. iPR
preparations were diluted 1:2 in PBS before mice were
injected with 50 μL of the inoculum. Mice in the positive
control group were also injected intramuscularly with 50
μL of the iPR inoculum. Body weight was monitored
daily, and mice losing more than 25% of their initialTable 2 The survival mice numbers in all groups after IAV cha
Group iPR pEGFP/Ag85-HA2 pEGFP
number 10 10weight were sacrificed and scored as dead. All experi-
ments were performed with institutional approval.
Seven days after the booster immunization, the mice
were challenged with IAV, as described previously
[12,23]. In brief, influenza A/PR/8/34 was harvested
from 10- to 11-day-old embryonated chickens eggs and
titrated in a plaque assay. Mice were anesthetized by in-
halation of isoflurane and challenged with IAV via intra-
nasal inoculation of two 50% mouse lethal doses
(MLD50) of PR8 virus diluted in PBS in a total volume
of 50 μL.
After IAV challenge, the numbers of survival mice in
all groups were showed in Table 2. Staphylococcal pneu-
monia was induced 14 days after IAV infection by intra-
nasal inoculation of 50 μl normal saline containing 2 × 104
colony forming units (cfu) of S. aureus (ATCC 25923) as
described previously [12,23]. The survival rate was moni-
tored from day 3 after infection with S. aureus.
Specimen collection
Specimen collection was performed according to the
method reported by Zhang et al. [26] and Tamura et al.
[29]. In brief, the first immune serum samples were
obtained from each mouse via tail bleeding 1 day before
the booster immunization. The second immune serum
samples were obtained from four randomly chosen mice
of each group by terminal cardiac bleeding under
anesthesia with chloroform at 8 days after the virus chal-
lenge. Spleens from the pEGFP/Ag85A group, pEGFP/c2
group, PBS group and iPR group were collected, and iso-
lated splenocytes were cultured. The spleens from the
pEGFP/Ag85A-HA2 and pEGFP/HA2 groups were col-
lected, and isolated splenocytes were cultured. The
supernatants of the splenocyte cultures were collected to
measure cytokine production. The trachea and left lungs
were collected and washed twice with 2 mL PBS con-
taining 0.1% BSA. The bronchoalveolar lavages were
centrifuged to remove cellular debris and were used for
virus titration. The right lungs were homogenized at 4°C
in five volumes of sterile isotonic saline with a Dounce
homogenizer. The lung homogenates were collected for
cytokine measurements.
For S. aureus titration, Western blotting and cytokine
measurements, spleens and lungs were collected from
four randomly chosen mice of each group under
anesthesia with chloroform at 48 h after S. aureus chal-
lenge. The lungs were harvested and homogenized at
4°C in five volumes of sterile isotonic saline with a
Dounce homogenizer. The lung homogenates werellenge
/HA2 pEGFP/Ag85 PBS pEGFP-C2
10 9 6 7
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ments. The collected spleen samples were lysed in RIPA
sample buffer (Boster Biotechnological, China) as
described by manufacturer’s instructions, and superna-
tants were collected to analyze expression of TLR2.
Antibody assay
The HA inhibition (HI) assay was performed according
to the method reported by Zhang et al. [26]. In brief, the
sera were two-fold serially diluted with PBS. Four HA
units of virus (A/PR/8/34, H1N1) in 25 μl per well were
added to a 96-well microtiter plate containing 25 μl of
diluted serum. Chicken erythrocytes in 50 μl 0.5% (v/v)
were added to each well after being mixed and incubated
at 4°C for 1 h. The plate was incubated at 4°C for 30–
45 min. The HI end-point titers were determined as the
reciprocal of the highest serum dilution that completely
inhibited hemagglutination.
The neutralisation assay was performed as previously
reported [6]. In brief, the sera from day 1 before the
booster immunization and day 8 after the virus challenge
were collected for neutralisation assay. 50 μl 2-fold serial
dilutions of treated sera were mixed with 50 μl five 50%
tissue culture infective doses (TCID50) of PR8 virus and
incubated for 45 min at 37°C. After washing with PBS,
Madin–Darby canine kidney (MDCK) cells (ATCC,
CCL-34) were inoculated with the 100 μl virus-antibody
mixtures. Following a 45-min incubation, DMEM sup-
plemented 2 μg/ml trypsin (Boster Biotechnological,
China)) and 3% bovine serum albumin (Beijing Biosyn-
thesis Biotechnology Co. LTD, China) was added to each
well of a 24-well plate. Each concentration was repeated
in four wells. The cytopathic effect (CPE) was assayed
after incubated at 37°C for 2 days. The titer of each sam-
ple, recorded as the dilution that reduced 50% of the
CPE, was calculated by the Reed–Muench method.
Cytokine measurements
Spleens were collected 8 days after the virus challenge.
Spleens were removed aseptically and processed as fol-
lows. Cells were segregated, washed, adjusted to a con-
centration of 5 × 106 cells per mL, and grown in a 96-
well flat-bottom plate (5 × 105 cells per well) in RPMI
1640 medium, supplemented with HEPES (N-2-hydro-
xyethylpiperazine-N’-2-ethanesulfonic acid), glutamine
and 10% heat-inactivated fetal calf serum (FCS). Cells
were stimulated with 0.5 μg concanavalin A (ConA) or
1.25 μg recombinant HA of A/PR/8/34 (Catalog Num-
ber: 11684-V08H, Sino Biological Inc, china) separately.
Cells were incubated at 37°C in a humidified CO2 incu-
bator, and supernatants were harvested after 72 h.
Supernatants were pooled and stored frozen at −20°C
until assay. Experiments were repeated three times, and
the results of one experiment are shown.Lung homogenates were collected on day 8 after infec-
tion with A/PR/8/34 and day 2 after infection with S.
aureus. For cytokine measurements, lung homogenates
from each group were diluted 1:2 in RIPA buffer (Boster
Biotechnological, China). Homogenates were centrifuged
at 1500 × g for 15 min at 4°C as described as instructed
by the manufacturer of the RIPA buffer, and superna-
tants were pooled and stored at −20°C until assays were
performed.
IFN-γ and IL-10 from lung homogenates and IFN-γ
from supernatants of splenocyte cultures were measured
using specific enzyme-linked immunosorbent assays
(ELISA; Boster Biotechnological, China) in accordance
with the manufacturer’s recommendations.
IAV titrations
The IAV titer assay was performed according to the
method reported by Zhang et al. [26]. In brief, the
bronchoalveolar lavage fluid of 8 days after the virus
challenge was 10-fold serially diluted. The bronchoalveo-
lar lavage dilutions were inoculated on confluent mono-
layers of Madin–Darby canine kidney (MDCK) cells
(ATCC, CCL-34) in 24-well plates. Each concentration
was repeated in four wells. The cytopathic effect (CPE)
was assayed after incubated at 37°C for 2 days. The virus
titer of each specimen, recorded as the 50% tissue cul-
ture infection dose (TCID50), was calculated by the
Reed–Muench method. The virus titer in each group
was presented as the mean ± SD of all specimens in each
group.
S.aureus titration
Whole lungs were collected from four randomly selected
mice by cardiac bleeding under anesthesia with chloro-
form at 48 h after S. aureus challenge. The whole lungs
were harvested and homogenized at 4°C in five volumes
of sterile isotonic saline with a Dounce homogenizer.
Serial 10-fold dilutions in sterile isotonic saline were
made from whole lung homogenates, and 50 μL volumes
were plated onto Luria-Bertani (LB) agar plates. LB agar
plates were incubated at 37°C, and the colonies were
counted after 16 h to determine the cfu.
Western blotting detection of TLR2
Spleens were lysed in RIPA sample buffer (Boster Bio-
logical Technology) per the manufacturer’s instructions,
and supernatants were collected to analyze expression of
TLR2 at 48 h after S. aureus challenge. The samples
were separated by SDS-PAGE (10%), and the proteins
were transferred to PVDF membranes, which were
blocked for 2 h in 5% nonfat dry milk in TBST (TBS
containing 0.05% Tween-20) and hybridized at 4°C over-
night in TBST with the primary antibodies (Boster Bio-
logical Technology) (anti-TLR2,1:400). After washing the
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they were incubated with 1:10,000 dilutions of HRP-
conjugated secondary antibodies (Boster Biotechno-
logical). The membranes were washed three times in
TBST, for 15 min each time, and the blots were visua-
lized with an electrochemiluminescence (ECL) system
(Boster Biological Technology).
RT-PCR detection of TLR2
Reverse transcription and PCR amplification of the
TLR2 transcript were performed as described by the
manufacturer (Transgene, China) of the EasyScript First-
Strand cDNA Synthesis SuperMix and 2× TransTaq
High Fidelity (HiFi) PCR SuperMix in a 50-μl reaction
mixture. The PCR primers for mouse GAPDH (531)
were 50-AAAACCTGACCTCCCTTGA-30 and 50-GTGC
AGCCTGGTGACATT-30. The PCR primers for mouse
TLR2 (410) were 50-TTTGCTCCTGCGAACTCC-30 and
50-CAGCTTAAAGGGCGGGTC-30. PCRs of pEGFP/
Ag85A-HA2, pEGFP/Ag85A and pEGFP/HA2 groups
were performed with GADPH primers and TLR2 pri-
mers. All PCRs were carried out simultaneouly in the
same conditions simultaneouly. For all PCRs, the condi-
tions were 5 min at 95°C, followed by 20 cycles consist-
ing of 30 seconds at 95°C, 30 seconds at 60°C, and
2 min at 72°C. After amplification, 10 μl of each PCR
product was electrophoresed on a 2% agarose gel and
visualized by ethidium bromide staining. PCR amplifica-
tion and sequencing using an ABI Prism 377XL DNA
sequencer (Invitrogen, China).
Statistical analysis
Data are presented as means ± SD. Group–group com-
parisons were analyzed using t-tests. Survival rates were
determined using the Kaplan-Meier method. P values <
0.05 were considered significant.
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